Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinsonʼs Disease and Hyperprolactinaemia

Autor: Wilhelm Haverkamp, Annamaria Colao, Miriam C. J. M. Sturkenboom, Gianluca Trifirò, Ron M. C. Herings, Douglas Ross, Katia M.C. Verhamme, R Zanettini, M. Mostafa Mokhles, Eva M. van Soest, Giampiero Mazzaglia, Guy van Camp, Jeanne P. Dieleman, Cynthia de Luise, Guy Brusselle, R Schade
Přispěvatelé: Trifiro, G, Mokhles, M, Dieleman, J, van Soest, E, Verhamme, K, Mazzaglia, G, Herings, R, de Luise, C, Ross, D, Brusselle, G, Colao, A, Haverkamp, W, Schade, R, van Camp, G, Zanettini, R, Sturkenboom, M, Medical Informatics, Department of Psychology, Education and Child Studies, Trifirò, G, Mokhles, Mm, Dieleman, Jp, van Soest, Em, Colao, Annamaria, Sturkenboom, M. C., Epidemiology and Data Science
Rok vydání: 2012
Předmět:
Zdroj: Drug Safety, 35(2), 159-171. Adis
Drug Safety, 35(2), 159-171. Adis International Ltd
Trifirò, G, Mokhles, M M, Dieleman, J P, Soest, E M, Verhamme, K, Mazzaglia, G, Herings, R, Luise, C, Ross, D, Brusselle, G, Colao, A, Haverkamp, W, chade, R, Van Camp, G, Zanettini, R & Sturkenboom, M C 2012, ' Risk of cardiac valve regurgitation with dopamine agonist use in parkinsons disease and hyperprolactinaemia : A multi-country, nested case-control study ', Drug Safety, vol. 35, no. 2, pp. 159-171 . https://doi.org/10.2165/11594940-000000000-00000
ISSN: 0114-5916
DOI: 10.2165/11594940-000000000-00000
Popis: Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgitation (CVR) in persons with Parkinson’s disease. It is unclear whether the CVR risk is increased with ergot-dopamine agonist use in persons with hyperprolactinaemia, in whom the dose is much lower. Objective: The aim of the study was to explore the association between different dopamine agonists and CVR in patients with Parkinson’s disease or hyperprolactinaemia. Design: Nested case-control studies conducted separately in cohorts of Parkinson’s disease and hyperprolactinaemia patients. Cases were patients who developed newly diagnosed CVR. Controls were CVR-free patients from the same cohorts and were matched to cases by age, sex, database and calendar year. Setting and Patients: Study patients were identified from over 4.5 million persons in The Health Improvement Network (THIN; UK), Health Search (Italy), and Integrated Primary Care Information (IPCI; the Netherlands) general practice databases in the years 1996–2007. The Parkinson’s disease cohort included new users of dopamine agonists or levodopa, while the hyperprolactinaemia cohort included new users or non-users of dopamine agonists. Main Outcome Measure: Risk of newly diagnosed CVR with dopamine agonist use compared with levodopa use in the Parkinson’s disease cohort, and dopamine agonist-naive patients in the hyperprolactinaemia cohort. Results: In the Parkinson’s disease cohort (7893 dopamine agonist users, 11 766 levodopa users), 85 incident CVR cases were identified. Increased CVR risk was observed for ergot dopamine agonists (adjusted OR [ORadj] 3.82; 95% CI 2.14, 6.81), but not for non-ergot dopamine agonists (ORadj 1.20; 95% CI 0.63, 2.29). In the hyperprolactinaemia cohort (6740 dopamine agonist users and 14299 dopamine agonist-naive patients), 37 CVR cases were identified during a mean follow-up of 4.5 years and 3.5 years for new users and non-users of dopamine agonists, respectively. However, no association with ever use of ergot dopamine agonists was observed (ORadj 0.47; 95% CI 0.20,1.19). Conclusion: Ergot-derived dopamine agonists are associated with an increased risk of CVR in Parkinson’s disease but not in hyperprolactinaemia patients.
Databáze: OpenAIRE
Externí odkaz: